Variation in hydration use after reinfusion of autologous stem cells in dimethyl sulfoxide (DMSO): a survey of EBMT centers

Résumé

Abstract Dimethyl sulfoxide (DMSO) is commonly used in hematopoietic stem cell (HSC) cryopreservation with various strategies employed to reduce DMSO related toxicity. A survey was conducted among EBMT centers to investigate the use of hydration following reinfusion of autologous HSCs in DMSO. Sixty-four questionnaires from 64 centers were analyzed. Fifty-four centers (84.3 %) gave hydration post-reinfusion of autologous HSC’s. Eighteen centers (28.1%) gave hydration depending on patient characteristics or the regimen of chemotherapy chosen. Two centers (3.1%) gave hydration only when there was insufficient oral intake. Ten centers (15.6%) stated they never gave post-reinfusion hydration. The most frequently reported reason to start post-reinfusion hydration was ‘to protect the kidneys from DMSO’ and ‘to flush out DMSO’ (84.3%). In 62.8% of responses, multiple reasons for hydration were cited, not only related to DMSO. No consensus in hydration fluid or volume was observed. Evidence is lacking to suggest hydration post-reinfusion reduces the toxicity of DMSO. Further research is necessary to explore the use of hydration post-reinfusion of stem cells. Existing knowledge surrounding use of lower concentrations of DMSO to reduce toxicity of DMSO for patients receiving an autologous stem cell transplantation, could be explored.

Citer ce document

Accès au document

Ce document est hébergé sur son dépôt institutionnel d'origine.

Auteur(s)

Statistiques

Consultations : 1

Téléchargements : 0